Lv61
1680 积分 2022-08-19 加入
A manganese-oxide nano-rambutan as the intrinsic modifier for hypericin delivery and triple-negative breast cancer treatment
2小时前
已完结
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
10天前
已完结
Protein Adsorption of In-line Intravenous Infusion Filter and the Corresponding Mitigation Plans
18天前
已关闭
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
19天前
已完结
SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation
1个月前
已完结
SLEDAI-2K for a 30-day window
1个月前
已完结
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia
1个月前
已完结
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
1个月前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
1个月前
已完结
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
皖公网安备34019202002308
